Eurofins strengthens its footprint in food and agroscience testing in Japan with new acquisitions

Eurofins Scientific (EUFI.PA), the world leader in food and agroscience testing services, announces the acquisitions of Japan Analytical Chemistry Consultants Co. Ltd. (“JACC”) and Ecopro Research K.K. (“Ecopro”). JACC is one of the largest independent agroscience testing laboratories in Japan and Ecopro is a leading food testing laboratory in Japan.

JACC is one of the largest Japanese independent GLP pesticide residue laboratories for agrochemical-registration, with more than 40 years of chemical testing experience and know-how. JACC has the accreditation from the Japanese Ministry of Agriculture, Forestry and Fisheries (MAFF), and serves chemical and agrochemical clients by offering pesticide analyses for river water, air and soil samples as well as analyses for active agrochemical ingredients and formulations. With accreditations from the Japanese Ministry of Health, Labor and Welfare (MHLW) and MAFF, Ecopro provides food testing services, including pesticide residue testing, nutrition analyses, and microbiology testing. Ecopro focuses specifically on tea samples and metabolome analysis for functional food. JACC and Ecopro employ 40 and 30 staff, respectively.

The two acquisitions reinforce Eurofins’ leadership position in the pesticide residue food market and provide Eurofins an entry in the agroscience market in Japan. The acquisition of Ecopro complements Eurofins’ existing local food-testing capabilities and is strategically located in Shizuoka, the largest tea-producing area in Japan.

Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisitions of JACC and Ecopro have a good strategic fit with Eurofins’ existing food and agroscience testing businesses and will help to expand our offerings in Japan. These acquisitions will reinforce the Groups’ growing footprint in Asia Pacific, and are a clear demonstration of our strong commitment in this geographical region. We look forward to providing JACC and Ecopro access to the full capabilities of the Eurofins network.”

For more information, please visit www.eurofins.com or contact:

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 375 laboratories across 41 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.